secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-07-14T20:00:31+00:00
Accession:  0001493152-26-033171
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027
--------------------------------------------------------------------------------

- 17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.
- CEO Vuong Trieu receives 2,000 RSUs; CMO Anthony Maida and CBO Saran Saund each receive 1,500; CFO Amit Shah receives 1,500.
- RSUs vest only if common stock uplists to a national exchange (e.g., Nasdaq, NYSE) on or before June 30, 2027, plus 6 months service.
- If uplisting does not occur by June 30, 2027, all RSUs expire; change in control accelerates full vesting.
- Potential dilution: up to 17.8 million common shares if all RSUs vest and Preferred converted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/0001493152-26-033171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer